NCT06481306

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 184 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

Conditions

• Anemia, Sickle Cell
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	BMS-986470	Specified dose on specified days
DRUG	Placebo	Specified dose on specified days
DRUG	Famotidine	Specified dose on specified days

Timeline

• Start date: 2024-07-17
• Primary completion: 2027-01-06
• Completion: 2027-11-16
• First posted: 2024-07-01
• Last updated: 2026-03-17

Locations

19 sites across 3 countries: United States, France, United Kingdom

Regulatory

• FDA-regulated drug study